XRCC2 Antibody (7B7/3): sc-53470
- XRCC2 Antibody (7B7/3) is a mouse monoclonal IgG1 provided at 200 µg/ml
- raised against human XRCC2
- recommended for detection of XRCC2 of human origin by WB
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for XRCC2 Antibody (7B7/3). This work is in progress.
QUICK LINKS
XRCC2 Antibody (7B7/3) is a mouse monoclonal IgG1 antibody that detects XRCC2 protein of human origin by western blotting (WB). Anti-XRCC2 antibody (7B7/3) plays a crucial role in the maintenance of genomic integrity, as XRCC2 is essential for the repair of DNA double-strand breaks through homologous recombination, a process vital for accurate DNA repair and chromosome stability during cell division. XRCC2 is primarily located in the nucleus, where XRCC2 participates in repair mechanisms that safeguard cellular genetic material from damage caused by environmental factors or cellular processes. XRCC2′s nuclear localization ensures ready availability to interact with other key players in the DNA repair pathway, such as Rad51, which is critical for the homologous recombination process. Deficiencies in XRCC2 can lead to increased susceptibility to genomic instability and various diseases, including cancer, highlighting XRCC2′s significance in cellular health and disease prevention. XRCC2 (7B7/3) antibody′s specific reactivity to human XRCC2 makes this monoclonal antibody an invaluable tool for researchers studying DNA repair mechanisms and their implications in human health.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
XRCC2 Antibody (7B7/3) References:
- Xrcc2 modulates spontaneous and radiation-induced tumorigenesis in Apcmin/+ mice. | Haines, JW., et al. 2010. Mol Cancer Res. 8: 1227-33. PMID: 20671066
- XRCC2 promotes colorectal cancer cell growth, regulates cell cycle progression, and apoptosis. | Xu, K., et al. 2014. Medicine (Baltimore). 93: e294. PMID: 25526472
- XRCC2 as a predictive biomarker for radioresistance in locally advanced rectal cancer patients undergoing preoperative radiotherapy. | Qin, CJ., et al. 2015. Oncotarget. 6: 32193-204. PMID: 26320178
- XRCC2 Regulates Replication Fork Progression during dNTP Alterations. | Saxena, S., et al. 2018. Cell Rep. 25: 3273-3282.e6. PMID: 30566856
- Inherited variants in XRCC2 and the risk of breast cancer. | Kluźniak, W., et al. 2019. Breast Cancer Res Treat. 178: 657-663. PMID: 31463769
- Significant value of XRCC2 and XRCC9 expression in the prognosis of human ovarian carcinoma. | Liu, Y., et al. 2021. J Cancer. 12: 6254-6264. PMID: 34539898
- XRCC2 Arg188His polymorphism and colorectal cancer risk: a meta-analysis. | Wang, Z., et al. 2021. J Int Med Res. 49: 3000605211039473. PMID: 34648414
- PARP inhibitor olaparib enhances the efficacy of radiotherapy on XRCC2-deficient colorectal cancer cells. | Qin, C., et al. 2022. Cell Death Dis. 13: 505. PMID: 35643812
- Association between XRCC2 Arg188His Polymorphism and Breast Cancer Susceptibility: A Systematic Review and Meta-Analysis. | Dastgheib, SA., et al. 2024. Asian Pac J Cancer Prev. 25: 43-55. PMID: 38285766
- XRCC2 knockdown effectively sensitizes esophageal cancer to albumin-paclitaxel in vitro and in vivo. | Xu, J., et al. 2024. Biochem Genet.. PMID: 39048769
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
XRCC2 Antibody (7B7/3) | sc-53470 | 200 µg/ml | $322.00 |